Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.44) by 4.86 percent. This is a 11.04 percent increase over losses of $(1.54) per share from the
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.44) by 4.86 percent. This is a 11.04 percent increase over losses of $(1.54) per share from the same period last year. The company reported quarterly sales of $47.557 million which beat the analyst consensus estimate of $41.879 million by 13.56 percent. This is a 2.36K percent increase over sales of $1.936 million the same period last year.